Surrozen Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.509
- Today's High:
- $0.531
- Open Price:
- $0.526
- 52W Low:
- $0.343
- 52W High:
- $2.84
- Prev. Close:
- $0.521
- Volume:
- 23295
Company Statistics
- Market Cap.:
- $16.88 million
- Book Value:
- 1.801
- Revenue TTM:
- $12.50 million
- Operating Margin TTM:
- -315.47%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -29.32%
- Return on Equity TTM:
- -52.25%
Company Profile
Surrozen Inc had its IPO on 2021-01-11 under the ticker symbol SRZN.
The company operates in the Healthcare sector and Biotechnology industry. Surrozen Inc has a staff strength of 74 employees.
Stock update
Shares of Surrozen Inc opened at $0.53 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.51 - $0.53, and closed at $0.51.
This is a -2.11% slip from the previous day's closing price.
A total volume of 23,295 shares were traded at the close of the day’s session.
In the last one week, shares of Surrozen Inc have slipped by -7.61%.
Surrozen Inc's Key Ratios
Surrozen Inc has a market cap of $16.88 million, indicating a price to book ratio of 0.2138 and a price to sales ratio of 0.
In the last 12-months Surrozen Inc’s revenue was $12.50 million with a gross profit of $0 and an EBITDA of $-37509000. The EBITDA ratio measures Surrozen Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Surrozen Inc’s operating margin was -315.47% while its return on assets stood at -29.32% with a return of equity of -52.25%.
In Q2, Surrozen Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Surrozen Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.15 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Surrozen Inc’s profitability.
Surrozen Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 1.0102. Its price to sales ratio in the trailing 12-months stood at 0.
Surrozen Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $64.00 million
- Total Liabilities
- $6.45 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $83000
- Dividend Payout Ratio
- 0%
Surrozen Inc ended 2024 with $64.00 million in total assets and $0 in total liabilities. Its intangible assets were valued at $64.00 million while shareholder equity stood at $55.06 million.
Surrozen Inc ended 2024 with $0 in deferred long-term liabilities, $6.45 million in other current liabilities, 3000.00 in common stock, $-202337000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $36.50 million and cash and short-term investments were $53.40 million. The company’s total short-term debt was $2,364,000 while long-term debt stood at $0.
Surrozen Inc’s total current assets stands at $57.58 million while long-term investments were $0 and short-term investments were $16.90 million. Its net receivables were $1.98 million compared to accounts payable of $186000.00 and inventory worth $0.
In 2024, Surrozen Inc's operating cash flow was $0 while its capital expenditure stood at $83000.
Comparatively, Surrozen Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.51
- 52-Week High
- $2.84
- 52-Week Low
- $0.343
- Analyst Target Price
- $2.25
Surrozen Inc stock is currently trading at $0.51 per share. It touched a 52-week high of $2.84 and a 52-week low of $2.84. Analysts tracking the stock have a 12-month average target price of $2.25.
Its 50-day moving average was $0.68 and 200-day moving average was $0.69 The short ratio stood at 1.02 indicating a short percent outstanding of 0%.
Around 838.9% of the company’s stock are held by insiders while 6284.3% are held by institutions.
Frequently Asked Questions About Surrozen Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. The company is developing antibody-based therapeutics with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcoholic hepatitis and asialoglycoprotein receptor 1; and SZN-1326, a bi-specific antibody, which is in Phase 1b clinical trial for the treatment of moderate to severe inflammatory bowel disease, Frizzled, and LRP receptors. The company also develops SZN-413, a Fzd4 targeted bi-specific antibody, which is in preclinical stage for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. was founded in 2015 and is based in South San Francisco, California.